PTC Therapeutics, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-66.0% vs price
Base Case (Median)
-10.9% vs price
Bull Case (75th pct.)
21.1% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $64.96 | -10.9% | High (40%) |
| EV/EBITDA | $111.61 | 53.1% | Medium (20%) |
| Earnings Power Value | $-15.44 | -121.2% | Medium (50%) |
Based on 3 out of 8 methods, PTCT appears fairly valued at the current price of $72.88. The base case fair value of $64.96 implies 10.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.